Start here if you're new
what it is
Protara is a clinical-stage biotech trying to turn three drug programs into future sales in cancer and rare disease.
how it gets paid
Last year Protara Therapeutics made n/a in revenue.
what just happened
The latest reported quarter showed -$0.37 EPS, a miss versus the -$0.34 consensus cited in recent coverage.
At a glance
B balance sheet — gets the job done, barely
45/100 earnings predictability — expect surprises
-$2.17 fy2024 eps est
1.45 beta
~$284M market cap
xvary composite: 62/100 — average
What they do
Protara is a clinical-stage biotech trying to turn three drug programs into future sales in cancer and rare disease.
The edge is focus. Protara has 28 employees and just a few shots on goal, so your bet is concentrated on programs management knows best. Clinical-stage biotech moat → a narrow scientific niche and regulatory progress → so what: if TARA-002 or IV Choline Chloride works, a company with $0 trailing revenue can look very different fast.
How they make money
n/a
annual revenue
The products that matter
cell therapy for bladder cancer
TARA-002
68% complete response rate · phase 2
it showed a 68% complete response rate in phase 2. that's the lead asset, and it does most of the equity work because there is no approved product behind it.
lead program
intravenous rare-disease therapy
IV Choline
phase 2 program
it's the second program and still in phase 2. the current snapshot data on this asset is thin, which matters because thin disclosure makes it harder for you to underwrite the backup plan.
second shot
Key numbers
$2.17
FY2024 EPS
EPS → profit per share → so what: Protara still burned money in 2024, but the loss improved from -$3.57 in 2023 to -$2.17 in 2024.
5/100
price stability
Price stability → how calm the stock has been → so what: a 5 out of 100 score tells you this name has been the opposite of calm.
1.45
beta
Beta → how much the stock moves versus the market → so what: Protara has historically moved about 45% more than the market.
B
balance sheet
Balance sheet grade → a snapshot of financial condition → so what: for a company with $0M trailing revenue, a B is one of the few stabilizers you have.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 1 — safer than 95% of stocks
- price stability 5 / 100
B — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for TARA right now.
source: institutional data · return history unavailable
What just happened
missed estimates
The latest reported quarter showed -$0.37 EPS, a miss versus the -$0.34 consensus cited in recent coverage.
This is still a pre-revenue biotech story, so earnings mostly track R&D spending and trial timing. The louder fact is simpler: trailing revenue remains $0M, so investors are still underwriting future data, not current sales.
$0M
ttm revenue
$0.37
latest eps
$197.9M
cash and investments
the number that mattered
$197.9M matters most because cash is runway, and runway is survival when your revenue is still $0M.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the top risk is TARA-002 clinical disappointment. this company has zero product revenue, so there is no boring legacy business to catch the fall.
med
TARA-002 fails to hold up in the next dataset
The lead program posted a 68% complete response rate in phase 2. If the next readout from roughly 25 patients lands well below that signal, the core thesis breaks fast because most of the valuation sits on that one asset.
This risk hits the whole story at once: sentiment, valuation, and the company's next financing conversation.
med
cash burn forces dilution before the story matures
A $57.4M annual loss against $197.9M in cash gives the company time, not immunity. If spending stays elevated while both programs advance, fresh capital can show up before investors get the clean data they want.
No revenue means every financing decision shows up in your ownership percentage.
med
the backup plan is thinner than the headline pipeline suggests
This is a two-program company, and the current page data on IV Choline is sparse. That matters because a thin second asset makes it harder for the market to absorb any slip in TARA-002 timelines or efficacy.
A thin pipeline can turn one setback into a full reset of how investors value the company.
With zero revenue, $197.9M in cash, and a $57.4M annual loss, almost all of today's equity value rests on clinical progress and how long that cash lasts.
source: institutional data · regulatory filings · risk analysis
Pay attention to
catalyst
TARA-002 interim data
Expected in the first quarter of 2026 from roughly 25 patients. This is the number that can reset the whole stock.
cash
burn versus $197.9M on hand
The quarter-to-quarter loss matters more than EPS aesthetics. If burn climbs, financing risk moves closer.
pipeline
whether IV Choline becomes a real second leg
Right now TARA-002 does most of the valuation work. Any cleaner update on the second program matters because this is still only a two-asset story.
sentiment
the gap between $6.51 and the $25.83 target
That spread is either a bargain or a warning label. It narrows only if the next data release gives the market something concrete to trust.
Analyst rankings
earnings predictability
45 / 100
in human-speak, analysts do not have a clean operating model here — expect estimates to move around.
beta
1.45
This has moved more than the market. That fits a small clinical-stage biotech where one trial update can outweigh the tape.
risk rank
1
The balance sheet screens safer than most stocks on this system. That helps with financing risk. It does not protect you from bad data.
source: institutional data
Institutional activity
institutional ownership data for TARA is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$7
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive